Target Name: CD1D
NCBI ID: G912
Other Name(s): thymocyte antigen CD1D | R3G1 | CD1d molecule, transcript variant 1 | CD1D_HUMAN | CD1A | CD1d molecule | CD1d | HMC class I antigen-like glycoprotein CD1D | CD1D variant 1 | CD1D antigen, d polypeptide | R3 | T-cell surface glycoprotein CD1d | Antigen-presenting glycoprotein CD1d | differentiation antigen CD1-alpha-3 | MGC34622 | Antigen-presenting glycoprotein CD1d (isoform 1)

CD1D: A Potential Drug Target and Biomarker for Thymocyte-Induced Allergies

Allergies are a common condition that affects millions of people worldwide, causing significant discomfort, itching, and even life-threatening reactions. Thymocyte-induced allergies, in particular, have been identified as a promising area for drug development due to their specific mechanisms and the potential for personalized treatments. One of the major allergens involved in thymocyte-induced allergies is CD1D, a type of molecule found on the surface of thymocytes, which are a type of immune cell that plays a crucial role in the development and maturation of T-cells.

In this article, we will discuss CD1D, its potential as a drug target and biomarker for thymocyte-induced allergies, and the ongoing research in this field.

CD1D: Structure and Function

CD1D is a cell surface molecule that consists of a perforinic acid-containing domain and a cytoplasmic region. It is expressed in a variety of tissues, including thymus, spleen, and peripheral blood cells, and has been shown to play a critical role in thymocyte function and development.

CD1D has been shown to interact with several other molecules, including cytokines, chemokines, and immune cells. Its functions include regulating T-cell development and function, cell survival, and immune surveillance.

Potential as a Drug Target

The CD1D molecule has been identified as a potential drug target for thymocyte-induced allergies due to its unique structure and its involvement in the development of T-cells. Several studies have shown that inhibiting CD1D can prevent the development of experimental thymocyte-induced allergies, suggesting that targeting this molecule may be an effective way to treat allergies.

In addition, several compounds have been shown to interact with CD1D and to inhibit its activity in a variety of experimental models of thymocyte-induced allergies, including models of atopic dermatitis and grass pollen allergy.

CD1D as a Biomarker

CD1D has also been identified as a potential biomarker for thymocyte-induced allergies. The molecule can be expressed and purified from various tissues, including thymus, spleen, and blood, making it a promising candidate for use as a diagnostic marker in clinical settings.

CD1D has been shown to be expressed in the blood cells of patients with thymocyte-induced allergies, and its levels have been correlated with the severity of symptoms. Additionally, studies have shown that changes in CD1D levels can be associated with the development of new allergies, providing insight into the potential role of this molecule in the development of these conditions.

Current Research

CD1D is a relatively new molecule, and there is ongoing research into its functions and potential as a drug target and biomarker for thymocyte-induced allergies.

One of the main areas of research is the study of the molecular mechanisms underlying CD1D's role in thymocyte-induced allergies. This includes studies of its interaction with other molecules involved in the development of allergies, as well as its role in regulating T-cell development and function.

Another area of research is the development of compounds that can inhibit CD1D's activity in thymocyte-induced allergies. This includes studies of the efficacy of these compounds in animal models of allergies and human clinical trials.

Conclusion

CD1D is a promising molecule for the development of drugs targeting thymocyte-induced allergies. Its unique structure and its involvement in the development of T-cells make it an attractive target for drug development. Additionally, its potential as a biomarker for these conditions makes it an important area of research.

Further studies are needed to fully understand the role of CD1D in thymocyte-induced allergies and

Protein Name: CD1d Molecule

Functions: Antigen-presenting protein that binds self and non-self glycolipids and presents them to T-cell receptors on natural killer T-cells

More Common Targets

CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27